Medicare might restrict patient access to Alzheimer’s treatment priced at $56,000 for a year’s supply to soften the financial blow to the federal insurance program’s budget.

“Whether or not that drug will be covered by Medicare and Medicaid is is an outstanding question, something that HHS will have to deal with,” said Health and Human Services Secretary Xavier Becerra last week.

Recommended Stories

Biden administration’s emergency abortion guidelines explained

Three members of FDA drug review panel resign over approval of $56K Alzheimer’s drug

Unexpected $36K air ambulance bills expected to be history under new ‘surprise billing’ rule